Sangamo Therapeutics, Inc. received a 180-day extension until April 27, 2026, to meet the Nasdaq minimum bid price requirement of $1.00 per share, reported on October 29, 2025. Failure to comply may result in delisting from Nasdaq. This situation is neutral in sentiment and significant for investors.